Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

68.97 +1.14 (+1.69%)
Streaming Delayed Price Updated: 1:20 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Good Times For Gold
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
EU Seeks Fines For AstraZeneca Over COVID-19 Vaccine Delays: Reuters
The European Union took on AstraZeneca Plc (NASDAQ: AZN) in a Brussels court and accused it of diverting doses promised to the bloc to other nations. EU’s... 
Via Benzinga
Exposures COVID-19
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic... 
Via Benzinga
Exposures COVID-19 Product Safety
Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters
Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro... 
Via Benzinga
Exposures COVID-19
Sterling At Five-Year High
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
Sanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters
Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax... 
Via Benzinga
Exposures COVID-19
UK Competition Watchdog Probes AstraZeneca's $39B Alexion Takeover
The U.K. competition regulator is mulling over AstraZeneca Plc’s (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (... 
Via Benzinga
Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?
It might seem bad at first glance. 
Via The Motley Fool
Exposures COVID-19
Pfizer/BioNTech or AstraZeneca COVID-19 Vaccine Effective Against Variant Found in India: CNBC
Two doses of either the Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) or AstraZeneca Plc (NASDAQ: AZN) - University of Oxford... 
Via Benzinga
Exposures COVID-19
Medical Miracles Inside Biotech ETFs
The events of the past year focused a lot of attention on game changing developments made possible by the global biotech industry. Of the major names Moderna is the one where the original research and... 
Via Talk Markets
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Pfizer Hits Deadlock With India Over Vaccine Indemnity Issue: Reuters
Pfizer Inc (NYSE: PFE) and the Indian government are at loggerheads over a demand by the company for legal protection from any claims linked to the use of its COVID-19... 
Via Benzinga
Japan Approves AstraZeneca's COVID Vaccine, But Puts Use on Hold Amid Blood Clot Concern
Along with the approval of Moderna’s COVID-19 vaccine, Japan’s regulatory authority has also approved AstraZeneca Plc’s (NASDAQ: AZN) COVID-... 
Via Benzinga
Exposures COVID-19
Better Mood Day
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
New Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment
AstraZeneca Plc (NASDAQ: AZN) has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating... 
Via Benzinga
Oxford/AstraZeneca Third Booster Strong Enough Against COVID-19 Variants, Study Shows: FT
Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported... 
Via Benzinga
Exposures COVID-19
G20 Countries Water Down US Push For COVID-19 IP Waiver: Reuters
G20, a global forum representing the world’s largest economies, has come forward supporting “voluntary licensing” of COVID-19 vaccine patents, the draft... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Oxford BioMedica To Manufacture More Doses Of AstraZeneca's COVID-19 Vaccine, Upgrades 2021 Outlook
Oxford BioMedica Plc (OTC: OXBDF) has raised its forecast for cumulative revenues from AstraZeneca Plc (NASDAQ: AZN) by the end of 2021 to more than... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
Another Tough Day For Markets
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” 
Via Talk Markets
US Poised To Dispatch 20M Additional COVID-19 Shots To Countries In Need: CNBC
President Joe Biden will announce that the U.S. plans to send at least 20 million additional coronavirus vaccine doses to foreign countries still being battered by the... 
Via Benzinga
Exposures COVID-19
Medical Stocks Jazz, Horizon Are Accelerating But Iqvia Is Hitting The Brakes
Jazz Pharmaceuticals and Horizon Therapeutics are among a cadre of accelerating medical stocks, while big names like Iqvia Holdings are hitting the brakes. 
Via Investor's Business Daily
Novavax Window of Opportunity Is Closing Fast
NVAX stock is in danger of repeating prior failures. The window of opportunity is closing and it's a movie investors have seen before. 
Via InvestorPlace
Exposures COVID-19
AstraZeneca's Farxiga Flunks Late-Stage COVID-19 Study
AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin... 
Via Benzinga
Exposures COVID-19
Barron's Latest Picks And Pans: DuPont, Stanley Black & Decker, Whirlpool And More
This weekend's Barron's helps investors identify stay-at-home stocks that still have room to run. Other featured articles discuss ways investors can hedge against... 
Via Benzinga
UK Study Answers Question If Two Doses Of COVID-19 Vaccines Can Be Mix-Matched?
Preliminary data from a U.K. clinical trial testing the benefits of mixing and matching COVID-19 vaccines showed that participants who received a mixed schedule of vaccines... 
Via Benzinga
Exposures COVID-19
A Down Day
The tech wreck continues because inflation will hurt the costly stock sector more than others. 
Via Talk Markets
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg
The U.K. government has reconsidered its plan to buy one million doses of AstraZeneca Plc’s (NASDAQ: AZN) anti-SARS-CoV-2 antibody, according to sources... 
Via Benzinga
Exposures COVID-19
European Union Announce Second Lawsuit Against AstraZeneca Over Delayed COVID-19 Vaccine Supply: Reuters
The European Union has reportedly launched a new lawsuit against AstraZeneca plc (NASDAQ: AZN) that could lead to financial sanctions for the company,... 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.